Mirvetuximab soravtansine - your experiences needed

[OvacomeSupport]

Dear All

We have been asked by the National Institute of Health and Care Excellence (NICE) to make a submission as part of their assessment for Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

It is really important that our submission reflects the thoughts and experiences of our community members and so we would be really keen to hear from anyone who has had mirvetuximab as part of their treatment for ovarian cancer. This is likely to be as part of a clinical trial, possibly GLORIOSA or MIRASOL.

If you have had this treatment, you live in the UK and would like to share your experiences with us, please contact us on [e-mail] or by calling 0800 008 7054. Alternatively, please feel free to comment below or send us a private message on the forum.

Thank you so much for all your help as always.

Best wishes,

Anna

Ovacome Support

[audhilly]

I am in the USA. I have HGSOC 3C. I had a year of stable disease during a trial of Mirv + Carbo. I believe Mirv should be available to patients because although it wasn’t the magic solution I had hoped, it gave me more relatively healthy time. I did have low platelets on several occasions but I generally did well. I have an aggressive cancer, so it was a godsend to me. There are other drugs coming out that also target folate receptor alpha and my oncologist has said I will be a candidate for those in the future.

[OvacomeSupport Partner My Ovacome Team in reply to audhilly]

Dear Audhilly

Thank you very much for taking the time to share your experience. This is really helpful information, we really appreciate it.

Best wishes

Anna